Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Hepatitis D Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Hepatitis D Overview | 8 | 1 |
| Pipeline Products for Hepatitis D Comparative Analysis | 9 | 1 |
| Hepatitis D Therapeutics under Development by Companies | 10 | 1 |
| Hepatitis D Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Hepatitis D Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Hepatitis D Products under Development by Companies | 15 | 1 |
| Hepatitis D Products under Investigation by Universities/Institutes | 16 | 1 |
| Hepatitis D Companies Involved in Therapeutics Development | 17 | 9 |
| Alnylam Pharmaceuticals, Inc. | 17 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 18 | 1 |
| Eiger BioPharmaceuticals, Inc. | 19 | 1 |
| F. Hoffmann-La Roche Ltd. | 20 | 1 |
| Globeimmune, Inc. | 21 | 1 |
| REPLICor Inc. | 22 | 1 |
| Rodos BioTarget GmbH | 23 | 1 |
| SomaGenics, Inc. | 24 | 1 |
| Spring Bank Pharmaceuticals, Inc. | 25 | 1 |
| Hepatitis D Therapeutics Assessment | 26 | 9 |
| Assessment by Monotherapy Products | 26 | 1 |
| Assessment by Target | 27 | 2 |
| Assessment by Mechanism of Action | 29 | 2 |
| Assessment by Route of Administration | 31 | 2 |
| Assessment by Molecule Type | 33 | 2 |
| Drug Profiles | 35 | 32 |
| ALN-HDV Drug Profile | 35 | 1 |
| ARC-520 Drug Profile | 36 | 7 |
| GI-18000 Drug Profile | 43 | 1 |
| lonafarnib Drug Profile | 44 | 3 |
| Myrcludex-B Drug Profile | 47 | 3 |
| peginterferon alfa-2a Drug Profile | 50 | 2 |
| peginterferon lambda-1a Drug Profile | 52 | 2 |
| RBT-05 Drug Profile | 54 | 1 |
| REP-2139 Drug Profile | 55 | 4 |
| REP-2165 Drug Profile | 59 | 1 |
| RNAi Oligonucleotide for Hepatitis D Drug Profile | 60 | 1 |
| SB-9200 Drug Profile | 61 | 5 |
| vanitaracin A Drug Profile | 66 | 1 |
| Hepatitis D Dormant Projects | 67 | 1 |
| Hepatitis D Product Development Milestones | 68 | 8 |
| Featured News &Press Releases | 68 | 1 |
| Sep 07, 2016: Eiger Announces Completion of Dosing in Phase 2 LOWR HDV 4 Study at Hannover Medical School | 68 | 1 |
| Jul 20, 2016: Eiger BioPharmaceuticals Announces Completion of Dosing in Phase 2 LOWR HDV 3 Study at National Institutes of Health | 68 | 1 |
| Jun 01, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Publication of Myrcludex B Clinical Results in Journal of Hepatology | 69 | 1 |
| May 25, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start Of Second Phase 2 Clinical Trial Of Myrcludex B In Chronic Hepatitis B/D Infection | 69 | 1 |
| Apr 29, 2016: Interim Results Of A Phase Ib/IIa Study Of The Entry Inhibitor Myrcludex B | 69 | 1 |
| Apr 04, 2016: Replicor to Make Three Presentations at EASL 2016 | 70 | 1 |
| Mar 30, 2016: Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver Meeting | 70 | 1 |
| Mar 23, 2016: Maxwell Biotech Venture Fund s Portfolio Company Hepatera Announces Start of Phase 2b clinical trial of Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic HBV and HDV Infection | 71 | 1 |
| Mar 14, 2016: Eiger BioPharmaceuticals Announces Completion of Enrollment of Phase 2 LOWR HDV 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus 4) Study at Hannover Medical School | 72 | 1 |
| Jan 19, 2016: Eiger BioPharmaceuticals Announces Completion of Enrollment of Phase 2 LOWR HDV 3 (LOnafarnib With Ritonavir in Hepatitis Delta Virus 3) Study at National Institutes of Health | 72 | 1 |
| Jan 06, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LOWR HDV 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus 4) Study at Hannover Medical School in Hannover, Germany | 73 | 1 |
| Jul 20, 2015: The Lancet Infectious Diseases Journal Publishes Results of Phase 2 Study of Lonafarnib in Hepatitis Delta Virus Infected Patients | 73 | 1 |
| Jun 30, 2015: Replicor Discloses Updated Clinical Trial Data to the Global Virus Hepatitis Summit in Berlin | 73 | 1 |
| Jun 10, 2015: Replicor to Present at the Israel Association for the Study of Liver Conference and the Global Virus Hepatitis Summit in Berlin in June | 74 | 1 |
| Apr 29, 2015: Significant Reduction of HBsAg and HDV RNA by REP 2139-Ca in Caucasian Patients with HBV / HDV Co-Infection | 74 | 2 |
| Appendix | 76 | 2 |
| Methodology | 76 | 1 |
| Coverage | 76 | 1 |
| Secondary Research | 76 | 1 |
| Primary Research | 76 | 1 |
| Expert Panel Validation | 76 | 1 |
| Contact Us | 76 | 1 |
| Disclaimer | 77 | 1 |